---
title: Cancer Biology and Therapeutics
description: A comprehensive textbook covering fundamental concepts in cancer biology and modern therapeutic approaches
---


## Section I: Fundamentals of Cancer Biology

### Chapter 1: The Building Blocks of Life - Normal Cell Biology
- [1.1 Introduction to Cells](/Chapter1/1_Introduction_to_Cells)
- [1.2 Cellular Organelles and Their Functions](/Chapter1/2_Cellular_Organelles_and_Their_Functions)
- [1.3 The Cell Cycle: Growth, Division, and Regulation](/Chapter1/3_The_Cell_Cycle_Growth_Division_and_Regulation)
- [1.4 DNA, RNA, and Protein Synthesis](/Chapter1/4_DNA_RNA_and_Protein_Synthesis)
- [1.5 Cell Communication and Signaling Pathways](/Chapter1/5_Cell_Communication_and_Signaling_Pathways)
- [1.6 Tissue Organization and Organ Systems](/Chapter1/6_Tissue_Organization_and_Organ_Systems)
- [1.7 Cell Death: Apoptosis and Necrosis](/Chapter1/7_Cell_Death_Apoptosis_and_Necrosis)
- [1.8 Cancer: Disruption of Normal Cell Biology](/Chapter1/8_Cancer_Disruption_of_Normal_Cell_Biology)
- [1.9 Summary](/Chapter1/9_Summary)

### Chapter 2: Introduction to Cancer - A Disease of Deregulation
- [2.1 Defining Cancer: Uncontrolled Growth and Invasion](/Chapter2/1_Defining_Cancer_Uncontrolled_Growth_and_Invasion)
- [2.2 History of Cancer Research](/Chapter2/2_History_of_Cancer_Research)
- [2.3 Hallmarks of Cancer](/Chapter2/3_Hallmarks_of_Cancer)
- [2.4 Terminology in Oncology](/Chapter2/4_Terminology_in_Oncology)
- [2.5 Epidemiology of Cancer](/Chapter2/5_Epidemiology_of_Cancer)
- [2.6 Summary](/Chapter2/6_Summary)

### Chapter 3: Cancer Epidemiology and Risk Factors
- [3.1 Global Cancer Incidence and Mortality](/Chapter3/1_Global_Cancer_Incidence_and_Mortality)
- [3.2 Genetic vs Environmental Contributions](/Chapter3/2_Genetic_vs_Environmental_Contributions)
- [3.3 Lifestyle-Associated Cancers](/Chapter3/3_Lifestyle_Associated_Cancers)
- [3.4 Environmental and Occupational Cancer Risks](/Chapter3/4_Environmental_and_Occupational_Cancer_Risks)
- [3.5 Cancer Health Disparities and Social Determinants](/Chapter3/5_Cancer_Health_Disparities_and_Social_Determinants)
- [3.6 Conclusion](/Chapter3/6_Conclusion)

### Chapter 4: Genetics and Genomic Instability in Cancer
- [4.1 DNA Structure and Replication](/Chapter4/1_DNA_Structure_and_Replication)
- [4.2 Mutations: Types and Consequences](/Chapter4/2_Mutations_Types_and_Consequences)
- [4.3 Chromosomal Abnormalities](/Chapter4/3_Chromosomal_Abnormalities)
- [4.4 DNA Repair Mechanisms and Their Failure in Cancer](/Chapter4/4_DNA_Repair_Mechanisms_and_Their_Failure_in_Cancer)
- [4.5 Genomic Instability](/Chapter4/5_Genomic_Instability)
- [4.6 Conclusion](/Chapter4/6_Conclusion)


### Chapter 5: Oncogenes
- [5.1 Discovery of Oncogenes](/Chapter5/1_Discovery_of_Oncogenes)
- [5.2 Proto-oncogenes: Normal Cellular Functions](/Chapter5/2_Proto_oncogenes_Normal_Cellular_Functions)
- [5.3 Mechanisms of Oncogene Activation](/Chapter5/3_Mechanisms_of_Oncogene_Activation)
- [5.4 Key Oncogene Families and Their Roles](/Chapter5/4_Key_Oncogene_Families_and_Their_Roles)
- [5.5 Clinical Implications and Therapeutic Targeting](/Chapter5/5_Clinical_Implications_and_Therapeutic_Targeting)
- [5.6 Conclusion](/Chapter5/6_Conclusion)

### Chapter 6: Tumor Suppressor Genes
- [6.1 Discovery and Function of Tumor Suppressor Genes](/Chapter6/1_Discovery_and_Function_of_Tumor_Suppressor_Genes)
- [6.2 Mechanisms of Tumor Suppressor Inactivation](/Chapter6/2_Mechanisms_of_Tumor_Suppressor_Inactivation)
- [6.3 Key Tumor Suppressor Genes](/Chapter6/3_Key_Tumor_Suppressor_Genes)
- [6.4 Clinical Implications of Tumor Suppressors](/Chapter6/4_Clinical_Implications_of_Tumor_Suppressors)
- [6.5 Future Directions](/Chapter6/5_Future_Directions)
- [6.6 Conclusion](/Chapter6/6_Conclusion)

### Chapter 7: Epigenetics in Cancer
- [7.1 Introduction to Epigenetics in Cancer](/Chapter7/1_Introduction_to_Epigenetics_in_Cancer)
- [7.2 DNA Methylation in Cancer](/Chapter7/2_DNA_Methylation_in_Cancer)
- [7.3 Histone Modifications in Cancer](/Chapter7/3_Histone_Modifications_in_Cancer)
- [7.4 Non-coding RNAs in Cancer](/Chapter7/4_Non-coding_RNAs_in_Cancer)
- [7.5 Polycomb and Trithorax Group Proteins](/Chapter7/5_Polycomb_and_Trithorax_Group_Proteins)
- [7.6 Epigenetic Reprogramming in Cancer](/Chapter7/6_Epigenetic_Reprogramming_in_Cancer)
- [7.7 Epigenetic Therapy](/Chapter7/7_Epigenetic_Therapy)
- [7.8 Clinical Applications and Future Directions](/Chapter7/8_Clinical_Applications_and_Future_Directions)
- [7.9 Conclusion](/Chapter7/9_Conclusion)

### Chapter 8: Cancer Etiology
- [8.1 Introduction](/Chapter8/1_Introduction)
- [8.2 Chemical Carcinogens](/Chapter8/2_Chemical_Carcinogens)
- [8.3 Radiation Carcinogenesis](/Chapter8/3_Radiation_Carcinogenesis)
- [8.4 Viral Carcinogenesis](/Chapter8/4_Viral_Carcinogenesis)
- [8.5 Bacterial Carcinogenesis](/Chapter8/5_Bacterial_Carcinogenesis)
- [8.6 Multifactorial Nature of Carcinogenesis](/Chapter8/6_Multifactorial_Nature_of_Carcinogenesis)
- [8.7 Conclusion](/Chapter8/7_Conclusion)


### Chapter 9: Cell Cycle Control and Cancer
- [9.1 Introduction](/Chapter9/1_Introduction)
- [9.2 Overview of the Cell Cycle and Its Regulation](/Chapter9/2_Overview_of_the_Cell_Cycle_and_Its_Regulation)
- [9.3 Cell Cycle Checkpoints](/Chapter9/3_Cell_Cycle_Checkpoints)
- [9.4 Cyclin Dependent Kinase Inhibitors](/Chapter9/4_Cyclin_Dependent_Kinase_Inhibitors)
- [9.5 Tumor Suppressor Genes](/Chapter9/5_Tumor_Suppressor_Genes)
- [9.6 Oncogenes and Cell Cycle Dysregulation](/Chapter9/6_Oncogenes_and_Cell_Cycle_Dysregulation)
- [9.7 Disruption of Cell Cycle Control in Cancer](/Chapter9/7_Disruption_of_Cell_Cycle_Control_in_Cancer)
- [9.8 Therapeutic Implications](/Chapter9/8_Therapeutic_Implications)
- [9.9 Conclusion](/Chapter9/9_Conclusion)

### Chapter 10: Apoptosis and Programmed Cell Death in Cancer
- [10.1 Introduction](/Chapter10/1_Introduction)
- [10.2 Pathways of Apoptosis: Intrinsic and Extrinsic](/Chapter10/2_Pathways_of_Apoptosis_Intrinsic_and_Extrinsic)
- [10.3 Evasion of Apoptosis by Cancer Cells](/Chapter10/3_Evasion_of_Apoptosis_by_Cancer_Cells)
- [10.4 Therapeutic Targeting of Apoptosis](/Chapter10/4_Therapeutic_Targeting_of_Apoptosis)
- [10.5 Summary](/Chapter10/5_Summary)

### Chapter 11: Cancer Metabolism - The Warburg Effect and Beyond
- [11.1 Introduction](/Chapter11/1_Introduction)
- [11.2 The Warburg Effect: Historical Discovery and Modern Understanding](/Chapter11/2_The_Warburg_Effect_Historical_Discovery_and_Modern_Understanding)
- [11.3 Glucose Metabolism in Cancer](/Chapter11/3_Glucose_Metabolism_in_Cancer)
- [11.4 Mitochondrial Function in Cancer](/Chapter11/4_Mitochondrial_Function_in_Cancer)
- [11.5 Lipid Metabolism in Cancer](/Chapter11/5_Lipid_Metabolism_in_Cancer)
- [11.6 Amino Acid Metabolism in Cancer](/Chapter11/6_Amino_Acid_Metabolism_in_Cancer)
- [11.7 Metabolic Interactions in the Tumor Microenvironment](/Chapter11/7_Metabolic_Interactions_in_the_Tumor_Microenvironment)
- [11.8 Therapeutic Targeting of Cancer Metabolism](/Chapter11/8_Therapeutic_Targeting_of_Cancer_Metabolism)
- [11.9 Future Directions and Clinical Translation](/Chapter11/9_Future_Directions_and_Clinical_Translation)
- [11.10 Conclusion](/Chapter11/10_Conclusion)



### Chapter 12: Angiogenesis
- [12.1 Introduction and Basic Concepts](/Chapter12/1_Introduction_and_Basic_Concepts)
- [12.2 Key Angiogenic Factors](/Chapter12/2_Key_Angiogenic_Factors)
- [12.3 Role of Hypoxia in Angiogenesis](/Chapter12/3_Role_of_Hypoxia_in_Angiogenesis)
- [12.4 Angiogenic Process and Stages](/Chapter12/4_Angiogenic_Process_and_Stages)
- [12.5 Angiogenesis in Cancer](/Chapter12/5_Angiogenesis_in_Cancer)
- [12.6 Anti-Angiogenic Therapy](/Chapter12/6_Anti_Angiogenic_Therapy)
- [12.7 Clinical Implications and Future Directions](/Chapter12/7_Clinical_Implications_and_Future_Directions)
- [12.8 Conclusion](/Chapter12/8_Conclusion)

### Chapter 13: Invasion and Metastasis - The Spread of Cancer
- [13.1 Introduction and Overview](/Chapter13/1_Introduction_and_Overview)
- [13.2 Epithelial-Mesenchymal Transition (EMT)](/Chapter13/2_Epithelial_Mesenchymal_Transition_EMT)
- [13.3 Matrix Metalloproteinases and Extracellular Matrix Degradation](/Chapter13/3_Matrix_Metalloproteinases_and_Extracellular_Matrix_Degradation)
- [13.4 Cell Morphology and Invasion Characteristics](/Chapter13/4_Cell_Morphology_and_Invasion_Characteristics)
- [13.5 Organ-Specific Metastasis](/Chapter13/5_Organ_Specific_Metastasis)
- [13.6 Circulating Tumor Cells](/Chapter13/6_Circulating_Tumor_Cells)
- [13.7 Angiogenesis and Metastasis](/Chapter13/7_Angiogenesis_and_Metastasis)
- [13.8 Molecular Mechanisms of Invasion](/Chapter13/8_Molecular_Mechanisms_of_Invasion)
- [13.9 Routes of Metastatic Spread](/Chapter13/9_Routes_of_Metastatic_Spread)
- [13.10 Clinical Implications and Therapeutic Considerations](/Chapter13/10_Clinical_Implications_and_Therapeutic_Considerations)
- [13.11 Conclusion](/Chapter13/11_Conclusion)

### Chapter 14: The Tumor Microenvironment
- [14.1 Components of the Tumor Microenvironment](/Chapter14/1_Components_of_the_Tumor_Microenvironment)
- [14.2 Interaction between Cancer Cells and the Stroma](/Chapter14/2_Interaction_between_Cancer_Cells_and_the_Stroma)
- [14.3 Inflammation and the Tumor Microenvironment](/Chapter14/3_Inflammation_and_the_Tumor_Microenvironment)
- [14.4 Extracellular Matrix Remodeling](/Chapter14/4_Extracellular_Matrix_Remodeling)
- [14.5 Clinical Implications and Future Directions](/Chapter14/5_Clinical_Implications_and_Future_Directions)

### Chapter 15: Cancer Stem Cells and Tumor Heterogeneity
- [15.1 Concept and Characteristics of Cancer Stem Cells](/Chapter15/1_Concept_and_Characteristics_of_Cancer_Stem_Cells)
- [15.2 Tumor Heterogeneity and Clonal Evolution](/Chapter15/2_Tumor_Heterogeneity_and_Clonal_Evolution)
- [15.3 Implications for Treatment Resistance](/Chapter15/3_Implications_for_Treatment_Resistance)
- [15.4 Clinical Implications and Future Directions](/Chapter15/4_Clinical_Implications_and_Future_Directions)

### Chapter 16: Tumor Immunology
- [16.1 Immune Surveillance and Escape](/Chapter16/1_Immune_Surveillance_and_Escape)
- [16.2 Tumor Antigens and Neoantigens](/Chapter16/2_Tumor_Antigens_and_Neoantigens)
- [16.3 Innate and Adaptive Immune Responses](/Chapter16/3_Innate_and_Adaptive_Immune_Responses)
- [16.4 Tumor-Induced Immune Suppression](/Chapter16/4_Tumor_Induced_Immune_Suppression)
- [16.5 Clinical Implications and Therapeutic Applications](/Chapter16/5_Clinical_Implications_and_Therapeutic_Applications)



## Section II: Cancer Prevention, Detection, and Diagnosis

### Chapter 17: Cancer Prevention and Screening
- [17.1 Introduction](/Chapter17/1_Introduction)
- [17.2 Primary Prevention: Lifestyle Modifications, Vaccinations](/Chapter17/2_Primary_Prevention_Lifestyle_Modifications_Vaccinations)
- [17.3 Secondary Prevention: Early Detection and Screening Programs](/Chapter17/3_Secondary_Prevention_Early_Detection_and_Screening_Programs)
- [17.4 Chemoprevention](/Chapter17/4_Chemoprevention)
- [17.5 Integration of Prevention Strategies](/Chapter17/5_Integration_of_Prevention_Strategies)
- [17.6 Conclusion](/Chapter17/6_Conclusion)

### Chapter 18: Cancer Detection and Diagnosis
- [18.1 Introduction](/Chapter18/1_Introduction)
- [18.2 Screening Methods](/Chapter18/2_Screening_Methods)
- [18.3 Imaging Techniques](/Chapter18/3_Imaging_Techniques)
- [18.4 Biopsy and Pathology: Histology, Cytology](/Chapter18/4_Biopsy_and_Pathology_Histology_Cytology)
- [18.5 Molecular Diagnostics: Biomarkers, Liquid Biopsy](/Chapter18/5_Molecular_Diagnostics_Biomarkers_Liquid_Biopsy)
- [18.6 Cancer Staging and Grading](/Chapter18/6_Cancer_Staging_and_Grading)
- [18.7 Conclusion](/Chapter18/7_Conclusion)

### Chapter 19: Principles of Cancer Therapy
- [19.1 Introduction](/Chapter19/1_Introduction)
- [19.2 Goals of Cancer Treatment](/Chapter19/2_Goals_of_Cancer_Treatment)
- [19.3 Multidisciplinary Approach to Cancer Care](/Chapter19/3_Multidisciplinary_Approach_to_Cancer_Care)
- [19.4 Personalized Medicine: Tailoring Treatment to the Individual](/Chapter19/4_Personalized_Medicine_Tailoring_Treatment_to_the_Individual)
- [19.5 Conclusion](/Chapter19/5_Conclusion)

## Section III: Treatment Approaches

### Chapter 20: Surgical Oncology
- [20.1 Introduction](/Chapter20/1_Introduction)
- [20.2 Principles of Cancer Surgery](/Chapter20/2_Principles_of_Cancer_Surgery)
- [20.3 Types of Surgical Procedures](/Chapter20/3_Types_of_Surgical_Procedures)
- [20.4 Minimally Invasive Surgery](/Chapter20/4_Minimally_Invasive_Surgery)
- [20.5 Reconstructive Surgery](/Chapter20/5_Reconstructive_Surgery)
- [20.6 Conclusion](/Chapter20/6_Conclusion)

### Chapter 21: Radiation Oncology
- [21.1 Principles of Radiotherapy: Biological Effects on Cells](/Chapter21/1_Principles_of_Radiotherapy_Biological_Effects_on_Cells)
- [21.2 Types of Radiation Therapy](/Chapter21/2_Types_of_Radiation_Therapy)
- [21.3 Technological Advances in Radiotherapy](/Chapter21/3_Technological_Advances_in_Radiotherapy)
- [21.4 Side Effects and Management](/Chapter21/4_Side_Effects_and_Management)
- [21.5 Conclusion and Clinical Takeaways](/Chapter21/5_Conclusion_and_Clinical_Takeaways)

### Chapter 22: Chemotherapy
- [22.1 Principles of Chemotherapy: Mechanism of Action](/Chapter22/1_Principles_of_Chemotherapy_Mechanism_of_Action)
- [22.2 Classes of Chemotherapeutic Agents](/Chapter22/2_Classes_of_Chemotherapeutic_Agents)
- [22.3 Pharmacology and Pharmacokinetics](/Chapter22/3_Pharmacology_and_Pharmacokinetics)
- [22.4 Drug Resistance](/Chapter22/4_Drug_Resistance)
- [22.5 Side Effects and Supportive Care](/Chapter22/5_Side_Effects_and_Supportive_Care)
- [22.6 Conclusion and Clinical Significance](/Chapter22/6_Conclusion_and_Clinical_Significance)

### Chapter 23: Hormonal Therapies
- [23.1 Introduction](/Chapter23/1_Introduction)
- [23.2 Hormone-Sensitive Cancers](/Chapter23/2_Hormone_Sensitive_Cancers)
- [23.3 Mechanisms of Hormonal Action](/Chapter23/3_Mechanisms_of_Hormonal_Action)
- [23.4 Anti-Estrogen Therapies](/Chapter23/4_Anti_Estrogen_Therapies)
- [23.5 Aromatase Inhibitors](/Chapter23/5_Aromatase_Inhibitors)
- [23.6 Anti-Androgen Therapies](/Chapter23/6_Anti_Androgen_Therapies)
- [23.7 GnRH Agonists and Antagonists](/Chapter23/7_GnRH_Agonists_and_Antagonists)
- [23.8 Steroidogenesis Inhibitors](/Chapter23/8_Steroidogenesis_Inhibitors)
- [23.9 Clinical Considerations and Patient Selection](/Chapter23/9_Clinical_Considerations_and_Patient_Selection)
- [23.10 Resistance Mechanisms and Second-Line Therapies](/Chapter23/10_Resistance_Mechanisms_and_Second_Line_Therapies)
- [23.11 Future Directions](/Chapter23/11_Future_Directions)
- [23.12 Conclusion](/Chapter23/12_Conclusion)

### Chapter 24: Targeted Therapies
- [24.1 Introduction](/Chapter24/1_Introduction)
- [24.2 Principles of Molecular Targeted Therapy](/Chapter24/2_Principles_of_Molecular_Targeted_Therapy)
- [24.3 Tyrosine Kinase Inhibitors (TKIs)](/Chapter24/3_Tyrosine_Kinase_Inhibitors_TKIs)
- [24.4 Monoclonal Antibodies](/Chapter24/4_Monoclonal_Antibodies)
- [24.5 PARP Inhibitors](/Chapter24/5_PARP_Inhibitors)
- [24.6 CDK Inhibitors](/Chapter24/6_CDK_Inhibitors)
- [24.7 Angiogenesis Inhibitors](/Chapter24/7_Angiogenesis_Inhibitors)
- [24.8 Resistance Mechanisms to Targeted Therapies](/Chapter24/8_Resistance_Mechanisms_to_Targeted_Therapies)
- [24.9 Clinical Considerations and Patient Selection](/Chapter24/9_Clinical_Considerations_and_Patient_Selection)
- [24.10 Future Directions](/Chapter24/10_Future_Directions)
- [24.11 Challenges and Limitations](/Chapter24/11_Challenges_and_Limitations)
- [24.12 Conclusion](/Chapter24/12_Conclusion)

### Chapter 25: Cancer Immunotherapy
- [25.1 Fundamentals of Cancer Immunology](/Chapter25/1_Fundamentals_of_Cancer_Immunology)
- [25.2 Immune Checkpoint Inhibitors](/Chapter25/2_Immune_Checkpoint_Inhibitors)
- [25.3 CAR T-cell Therapy and Other Adoptive Cell Therapies](/Chapter25/3_CAR_T_cell_Therapy_and_Other_Adoptive_Cell_Therapies)
- [25.4 Cancer Vaccines](/Chapter25/4_Cancer_Vaccines)
- [25.5 Cytokine Therapy](/Chapter25/5_Cytokine_Therapy)
- [25.6 Immune-Related Adverse Events](/Chapter25/6_Immune_Related_Adverse_Events)

### Chapter 26: Gene Therapy and Oncolytic Virotherapy
- [26.1 Principles of Gene Therapy for Cancer](/Chapter26/1_Principles_of_Gene_Therapy_for_Cancer)
- [26.2 Gene Editing Technologies](/Chapter26/2_Gene_Editing_Technologies)
- [26.3 Viral Vectors: Mechanisms of Action and Safety](/Chapter26/3_Viral_Vectors_Mechanisms_of_Action_and_Safety)
- [26.4 Oncolytic Virotherapy](/Chapter26/4_Oncolytic_Virotherapy)
- [26.5 Current Trials and Clinical Use](/Chapter26/5_Current_Trials_and_Clinical_Use)

### Chapter 27: Nanotechnology in Cancer
- [27.1 Nanoparticles for Drug Delivery](/Chapter27/1_Nanoparticles_for_Drug_Delivery)
- [27.2 Nanomaterials for Imaging and Diagnosis](/Chapter27/2_Nanomaterials_for_Imaging_and_Diagnosis)
- [27.3 Theranostics and Multifunctional Platforms](/Chapter27/3_Theranostics_and_Multifunctional_Platforms)


### Chapter 28: Clinical Trials and Regulatory Pathways
- [28.1 Trial Phases and Design](/Chapter28/1_Trial_Phases_and_Design)
- [28.2 FDA/EMA Approval Processes](/Chapter28/2_FDA_EMA_Approval_Processes)
- [28.3 Compassionate Use and Expanded Access](/Chapter28/3_Compassionate_Use_and_Expanded_Access)

### Chapter 29: Future Directions in Cancer Treatment Research
- [29.1 Introduction](/Chapter29/1_Introduction)
- [29.2 Liquid Biopsies and Circulating Tumor DNA for Monitoring and Early Detection](/Chapter29/2_Liquid_Biopsies_and_Circulating_Tumor_DNA_for_Monitoring_and_Early_Detection)
- [29.3 Artificial Intelligence and Machine Learning in Oncology](/Chapter29/3_Artificial_Intelligence_and_Machine_Learning_in_Oncology)
- [29.4 Organoids and Patient-Derived Xenografts for Drug Testing](/Chapter29/4_Organoids_and_Patient_Derived_Xenografts_for_Drug_Testing)
- [29.5 Microbiome and Cancer](/Chapter29/5_Microbiome_and_Cancer)
- [29.6 Metabolic Targeting Beyond the Warburg Effect](/Chapter29/6_Metabolic_Targeting_Beyond_the_Warburg_Effect)
- [29.7 Novel Combinatorial Approaches](/Chapter29/7_Novel_Combinatorial_Approaches)
- [29.8 Addressing Treatment Resistance and Relapse](/Chapter29/8_Addressing_Treatment_Resistance_and_Relapse)
- [29.9 Conclusion](/Chapter29/9_Conclusion)

### Chapter 30: Principles of Cancer Classification
- [30.1 Introduction](/Chapter30/1_Introduction)
- [30.2 Histopathological Classification](/Chapter30/2_Histopathological_Classification)
- [30.3 Anatomical Classification](/Chapter30/3_Anatomical_Classification)
- [30.4 Molecular and Genomic Classification](/Chapter30/4_Molecular_and_Genomic_Classification)
- [30.5 Conclusion](/Chapter30/5_Conclusion)


## Section IV: Specific Cancer Types

### Chapter 31: Solid Tumors by Organ/System
- [31.1 Introduction](/Chapter31/1_Introduction)
- [31.2 Breast Cancer](/Chapter31/2_Breast_Cancer)
- [31.3 Lung Cancer](/Chapter31/3_Lung_Cancer)
- [31.4 Colorectal Cancer](/Chapter31/4_Colorectal_Cancer)
- [31.5 Genitourinary Cancers](/Chapter31/5_Genitourinary_Cancers)
- [31.6 Gynecologic Cancers](/Chapter31/6_Gynecologic_Cancers)
- [31.7 Gastrointestinal Cancers](/Chapter31/7_Gastrointestinal_Cancers)
- [31.8 Head and Neck Cancers](/Chapter31/8_Head_and_Neck_Cancers)
- [31.9 Skin Cancers](/Chapter31/9_Skin_Cancers)
- [31.10 Clinical Implications and Future Directions](/Chapter31/10_Clinical_Implications_and_Future_Directions)
- [31.11 Summary](/Chapter31/11_Summary)

### Chapter 32: Central Nervous System Tumors
- [32.1 Introduction](/Chapter32/1_Introduction)
- [32.2 Glioblastoma Multiforme](/Chapter32/2_Glioblastoma_Multiforme)
- [32.3 Meningiomas](/Chapter32/3_Meningiomas)
- [32.4 Multidisciplinary Management](/Chapter32/4_Multidisciplinary_Management)
- [32.5 Future Directions and Research](/Chapter32/5_Future_Directions_and_Research)
- [32.6 Clinical Implications for Healthcare Providers](/Chapter32/6_Clinical_Implications_for_Healthcare_Providers)
- [32.7 Summary](/Chapter32/7_Summary)

### Chapter 33: Hematologic Malignancies
- [33.1 Introduction](/Chapter33/1_Introduction)
- [33.2 Leukemias](/Chapter33/2_Leukemias)
- [33.3 Lymphomas](/Chapter33/3_Lymphomas)
- [33.4 Plasma Cell Dyscrasias](/Chapter33/4_Plasma_Cell_Dyscrasias)
- [33.5 Diagnostic Approaches](/Chapter33/5_Diagnostic_Approaches)
- [33.6 Treatment Approaches](/Chapter33/6_Treatment_Approaches)
- [33.7 Prognosis and Outcomes](/Chapter33/7_Prognosis_and_Outcomes)
- [33.8 Special Populations](/Chapter33/8_Special_Populations)
- [33.9 Nursing and Supportive Care](/Chapter33/9_Nursing_and_Supportive_Care)
- [33.10 Future Directions](/Chapter33/10_Future_Directions)
- [33.11 Clinical Implications for Healthcare Providers](/Chapter33/11_Clinical_Implications_for_Healthcare_Providers)
- [33.12 Summary](/Chapter33/12_Summary)

### Chapter 34: Pediatric Cancers
- [34.1 Introduction](/Chapter34/1_Introduction)
- [34.2 Neuroblastoma](/Chapter34/2_Neuroblastoma)
- [34.3 Wilms Tumor](/Chapter34/3_Wilms_Tumor)
- [34.4 Medulloblastoma](/Chapter34/4_Medulloblastoma)
- [34.5 Conclusion](/Chapter34/5_Conclusion)

### Chapter 35: Rare and Orphan Cancers
- [35.1 Introduction](/Chapter35/1_Introduction)
- [35.2 Sarcomas](/Chapter35/2_Sarcomas)
- [35.3 Thymic Tumors](/Chapter35/3_Thymic_Tumors)
- [35.4 Gestational Trophoblastic Disease](/Chapter35/4_Gestational_Trophoblastic_Disease)
- [35.5 Adrenocortical Carcinoma](/Chapter35/5_Adrenocortical_Carcinoma)
- [35.6 Peritoneal and Primary Peritoneal Cancers](/Chapter35/6_Peritoneal_and_Primary_Peritoneal_Cancers)
- [35.7 Conclusion](/Chapter35/7_Conclusion)


## Section V: Survivorship and Special Considerations

### Chapter 36: Supportive Care and Palliative Care in Oncology
- [36.1 Introduction](/Chapter36/1_Introduction)
- [36.2 Management of Cancer-Related Symptoms](/Chapter36/2_Management_of_Cancer_Related_Symptoms)
- [36.3 Nutritional Support](/Chapter36/3_Nutritional_Support)
- [36.4 Psychological and Social Support](/Chapter36/4_Psychological_and_Social_Support)
- [36.5 Palliative Care Principles](/Chapter36/5_Palliative_Care_Principles)
- [36.6 End of Life Care](/Chapter36/6_End_of_Life_Care)
- [36.7 Conclusion](/Chapter36/7_Conclusion)

### Chapter 37: Cancer Survivorship
- [37.1 Introduction](/Chapter37/1_Introduction)
- [37.2 Long-Term Side Effects of Treatment](/Chapter37/2_Long_Term_Side_Effects_of_Treatment)
- [37.3 Psychosocial Challenges for Survivors](/Chapter37/3_Psychosocial_Challenges_for_Survivors)
- [37.4 Rehabilitation and Reintegration](/Chapter37/4_Rehabilitation_and_Reintegration)
- [37.5 Quality of Life after Cancer](/Chapter37/5_Quality_of_Life_after_Cancer)
- [37.6 Conclusion](/Chapter37/6_Conclusion)

### Chapter 38: Health Economics and Access to Cancer Care
- [38.1 Introduction](/Chapter38/1_Introduction)
- [38.2 Drug Pricing and Affordability](/Chapter38/2_Drug_Pricing_and_Affordability)
- [38.3 Global Disparities](/Chapter38/3_Global_Disparities)
- [38.4 Ethical and Policy Considerations](/Chapter38/4_Ethical_and_Policy_Considerations)
- [38.5 Conclusion](/Chapter38/5_Conclusion)